This is a letter to Roche requesting a voluntary license to the patents on risdiplam, a treatment for Spinal Muscular Atrophy (SMA).
KEI-Risdiplan-patent-license-request-8july2022
This was the August 5, 2022 response.
Roche-Response-to-Risdiplam-license-request–5Aug2022